Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Study: Obese People Have a Weak Immune System; polyDNA Recommends Gene-Eden-VIR and Novirin to Boost the Immune System Against Latent Viruses
  • USA - English


News provided by

PolyDNA

May 29, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX


Because obesity can damage expose the body to the negative effect of latent viral infections, we recommend that individuals take Gene-Eden-VIR or Novirin. - polyDNA

Post this

Rochester, NY (PRWEB) May 29, 2014 -- polyDNA has learned that a new study from Boston University researchers showed that obesity is associated with a weak immune system. In fact, for years researchers have noted that overweight individuals have difficulty clearing an infection. Dr. Salomon Amar said, “Now we understand that dysfunction in some of the mechanisms, as a result of the obesity, explain difficulty in clearing the infection and also the difficulty in wound healing (1).” This study adds to growing research, which shows that obese individuals show “an impaired immune response or immune function leading to increased chances for various infections.” (See the Obesity Action Coalition) (2). This means that overweight people have a lower ability to fight invading pathogens such as bacteria and viruses.

polyDNA recommends that individuals who suffer from obesity take Gene-Eden-VIR or Novirin. The formula of these natural antiviral products was shown to reduce symptoms of viral infections in two post-marketing clinical studies that followed FDA guidelines.

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. The formula of each contains 5 natural ingredients. These are selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. That's 4 plant extracts and 1 trace element. Each ingredient of Gene-Eden-VIR and Novirin was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the highest quality, safest, most effective natural ingredients that target latent viruses. Gene-Eden-VIR and Novirin are the only natural antiviral products that were tested in clinical studies. These studies showed that the formula reduced viral symptoms. These products can be ordered online at http://www.gene-eden-vir and http://www.novirin.com.

Which comes first? Obesity or a weak immune system?

Science is not sure which comes first: the decrease in the immune system, which leads to obesity, or obesity first, and then a decrease in the efficiency of the immune system.

Some scientists, like Professor Amar, Professor Marcos, and colleagues, believe that obesity damages the immune system. “Obesity shares with most chronic diseases the presence of an inflammatory component…the chronic inflammatory response has its origin in the links existing between the adipose tissue and the immune system. Obesity, like other states of malnutrition, is known to impair the immune function, altering leucocyte counts as well as cell-mediated immune responses.” (See The Proceedings of the Nutrition Society, from May 2012) (3). In other words, being overweight harms the ability of the immune system to protect the body from infection.

In contrast, Dr. Hanan Polansky presented a theory that says that a decrease in the efficiency of the immune system causes obesity. Dr. Polansky’s theory was presented in his ground breaking book, “Microcompetition with Foreign DNA and the Origin of Chronic Disease.” The theory identifies the origin of many chronic diseases, such as obesity. (See Microcompetition with Foreign DNA and the Origin of Chronic Disease, published in 2003) (4). Dr. Polansky’s theory further explains how foreign DNA fragments can cause obesity. The book has been read by more than 5,000 scientists around the world, and has been reviewed in more than 20 leading scientific journals.

The theory, in short, discusses how foreign DNA fragments, called N-boxes, cause most major diseases. When foreign N-boxes enter the body (naturally, or artificially, like through an injection of some treatment), they end up in the nucleus, where they attract scarce genetic resources. It is interesting that many common latent viruses have strong N-boxes in their DNA. They include the Epstein-Barr virus (EBV), Cytomegalovirus (CMV), Herpes Simplex virus (HSV), Varicella Zoster virus (VZV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Papillomavirus (HPV), and others. In fact, the CMV virus has the strongest N-box known to science. This N-box is so strong that human genes cannot compete with its power to attract the scarce genetic resources.

When this happens, a chronic disease, such as obesity, develops.

Research shows that obesity can also kill. “Severe obesity, in and of itself, has also been named a risk factor for increased severity of infection and death from the H1N1 influenza strain. Those affected by obesity may also be at risk for viruses like H1N1 because of less of an immune response to vaccinations (2).”

What can one do against the risks associated with obesity? If one believes in the theory that excess weight damages the immune system, then this individual should first lose weight. In contrast, if one believes that a deficient immune system increases the concentration of latent viruses, which in turn causes obesity, then this individual should find a way to decrease the concentration of latent viruses in the body.

How can one do this?

There are a few antiviral options. “A few antiviral drugs are available that were shown to inhibit EBV replication in cell culture. These drugs include the acyclic nucleoside analogues aciclovir, ganciclovir, penciclovir, and their respective prodrugs valaciclovir, valganciclovir and famciclovir, the acyclic nucleotide analogues cidofovir and adefovir, and the pyrophosphate analogue foscarnet. However, clinical studies have shown that these drugs are mostly ineffective in humans.” (See Pharmacology & Pharmacy, from September 2013) (5).

There are, however, natural antiviral products, such as Gene-Eden-VIR and Novirin, which have been shown in studies to be effective in reducing symptoms associated with viral infections.

“Because obesity can damage expose the body to the negative effect of latent viral infections, we recommend that individuals take Gene-Eden-VIR or Novirin. The formula of these natural antiviral products was designed to help the immune system target latent viruses.” – Mike Evans, polyDNA

Novirin shares the same formula as Gene-Eden-VIR. The difference between the two is that Novirin has higher quality, more expensive ingredients. The Novirin/Gene-Eden-VIR formula was tested in two post-marketing clinical studies published in September 2013 and March 2014, respectively, in the peer reviewed medical journal Pharmacy & Pharmacology (5).

Interested individuals can view the two published studies here, http://cbcd.net/Gene-Eden-VIR-Clinical-Study.php and http://cbcd.net/Gene-Eden-VIR-Decreases-Fatigue-Clinical-Study.php.

Up to 70% of those studied reported a decrease in symptoms associated with viral infections, and users of the Novirin/Gene-Eden-VIR formula experienced an increase in overall health (5).

Each ingredient of Novirin was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the highest quality, safest, most effective natural ingredients that target latent viruses.

A second clinical study showed that the Novirin/Gene-Eden-VIR formula decreased physical and mental fatigue. (See Pharmacology & Pharmacy, from March, 2014) (6).
To learn more about Novirin, visit http://www.novirin.com and about Gene-Eden-VIR, visit http://www.gene-eden-vir.com.

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Obesity Weakens Immune Response. Published on March 23, 2014.
http://abcnews.go.com/Health/Healthday/story?id=4509715

(2) Obesity Action Coalition - Obesity and the Immune System.
http://www.obesityaction.org/educational-resources/resource-articles-2/general-articles/obesity-and-the-immune-system

(3) Obesity, inflammation and the immune system. Published on May 7, 2012.
http://www.ncbi.nlm.nih.gov/pubmed/22429824

(4) CBCD - Microcompetition with Foreign DNA and the Origin of Chronic Disease.
http://www.cbcd.net/Book.php

(5) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php

Mike Davis, PolyDNA, http://gene-eden-kill-virus.com/, +1 5852509999, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.